Clinical trial · Interventional
Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life. However, few studies have examined the specific effect of HPV status (or knowledge of status) on the recovery/quality of sexuality following radiotherapy. It is against this backdrop that we propose a prospective longitudinal study specifically dedicated to investigating the sexual quality of life of women with HPV-positive pelvic cancer. This type of study will enable better quantification and description of sexual dysfunction occurring after treatment, and assessment of the impact of HPV carriage, with the future aim of guiding new prevention and management strategies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Pelvic Cancer | Malignant Pelvic Neoplasm | ALIAS | 0.90 |
| Vaginal Cancer | Malignant Vaginal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment of sexual quality of life | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SINGLE-ARM INTERVENTIONAL STUDY
- description
- Patients will be seen by the investigator at the radiotherapy clinic on enrolment, at 3 months and at 6 months (the 6-month visit will mark the end of the study)
- interventionNames
- Other: Assessment of sexual quality of life
Primary outcomes (1)
- measure
- To describe the quality of sexual life among patients treated (radiotherapy, with or without chemotherapy, and/or surgery) as part of the management of HPV-positive pelvic cancer.
- timeFrame
- at baseline, 3 months and 6 months after the end of all cancer treatment
- description
- Sexual quality of life scores obtained from the European EORTC QLQ-SH22 questionnaire
Secondary outcomes (2)
- measure
- To assess perceptions of, and the impact on sexuality of, the sexually transmitted nature (STI) of these cancers
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women aged 18 or over. 2. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis. 3. Patients being treated at the Montpellier Cancer Institute (ICM). 4. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection 5. Patient aware of her HPV status and how it is transmitted. 6. Indicated for external radiotherapy 7. Patient who has not received any oncological treatment prior to inclusion. 8. Patient who has given verbal consent. Exclusion Criteria: 1. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM). 2. Patients who are unwilling or unable to complete the study questionnaires. 3. Patients under guardianship, curatorship or court protection, 4. Patients for whom regular follow-up is impossible for psychological reasons, 5. Patients who do not speak French.
References
Publications (0)
Data not yet available